We were listening for manufacturing commentary, as you know we're tracking the target dates for the first 100MM doses distributed and administered closely. But if you care about PFE more broadly, it's interesting to note that Pfizer's new rare-disease meds Vyndaqel, Vyndamax reach blockbuster threshold despite pandemic hurdles. Specific comments from the call ( emphasis added):